Natural Killer/T Cell Lymphoma, Nasal Type: A Retrospective Clinical Analysis in North-Western China

Oncol Res Treat. 2016;39(1-2):45-52. doi: 10.1159/000442763. Epub 2016 Jan 22.

Abstract

Background: Extranodal natural killer (NK)/T cell lymphoma (ENKTL) is an aggressive non-Hodgkin's lymphoma with high mortality and poor prognosis despite radiotherapy and chemotherapy. The current analysis aimed to assess the pathological features, clinical features, and prognostic indicators of ENKTL.

Material and methods: 120 ENKTL patients were analyzed for pathologic diagnosis and clinical disease manifestations from April 2007 to October 2012. Complete remission, 2-year overall survival, and progression-free survival were analyzed.

Results: Compared with the nasal group, a greater percentage of patients in the non-nasal group intended to receive autologous stem cell transplantation had Epstein-Barr virus (EBV) DNA, Ann Arbor stage IV, Ki-67 expression ≥ 60%, and abnormal ferroprotein and β-microglobulin levels. The rate of complete remission in the non-nasal group was higher than that in the nasal group. The overall survival rate was 74.9% at 24 months. Patients receiving chemotherapy and radiotherapy were more likely to have disease progression compared with patients who received chemotherapy or radiotherapy alone.

Conclusions: Further understanding the pathological and clinical features of ENKTL will be critical for moving forward. Ki-67, β-microglobulin, EBV DNA, and primary site prognostic indicators may be useful to stratify patients into different risk groups, to gain insight into patient-specific treatments, and to potentially improve survival.

MeSH terms

  • Adolescent
  • Adult
  • Age Distribution
  • Aged
  • Aged, 80 and over
  • Chemoradiotherapy / mortality*
  • Chemoradiotherapy / statistics & numerical data
  • Child
  • China / epidemiology
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphoma, Extranodal NK-T-Cell / diagnosis
  • Lymphoma, Extranodal NK-T-Cell / mortality*
  • Lymphoma, Extranodal NK-T-Cell / therapy*
  • Male
  • Middle Aged
  • Nose Neoplasms / diagnosis
  • Nose Neoplasms / mortality*
  • Nose Neoplasms / therapy*
  • Prevalence
  • Retrospective Studies
  • Risk Factors
  • Sex Distribution
  • Survival Rate
  • Young Adult